Fibroblast growth factors: new insights, new targets in the management of diabetes
The fibroblast growth factor (FGF) family consists of 22 evolutionarily and structurally related proteins (FGF1 to FGF23; with FGF15 being the rodent ortholog of human FGF19). Based on their mechanism of action, FGFs can be categorized into intracrine, autocrine/paracrine and endocrine subgroups. Bo...
Saved in:
Published in | Minerva endocrinologica Vol. 42; no. 3; p. 248 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
01.09.2017
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The fibroblast growth factor (FGF) family consists of 22 evolutionarily and structurally related proteins (FGF1 to FGF23; with FGF15 being the rodent ortholog of human FGF19). Based on their mechanism of action, FGFs can be categorized into intracrine, autocrine/paracrine and endocrine subgroups. Both autocrine/paracrine and endocrine FGFs are secreted from their cells of origin and exert their effects on target cells by binding to and activating specific single-pass transmembrane tyrosine kinase receptors (FGFRs). Moreover, FGF binding to FGFRs requires specific cofactors, namely heparin/heparan sulfate proteoglycans or Klothos for autocrine/paracrine and endocrine FGF signaling, respectively. FGFs are vital for embryonic development and mediate a broad spectrum of biological functions, ranging from cellular excitability to angiogenesis and tissue regeneration. Over the past decade certain FGFs (e.g. FGF1, FGF10, FGF15/FGF19 and FGF21) have been further recognized as regulators of energy homeostasis, metabolism and adipogenesis, constituting novel therapeutic targets for obesity and obesity-related cardiometabolic disease. Until recently, translational research has been mainly focused on FGF21, due to the pleiotropic, beneficial metabolic actions and the relatively benign safety profile of its engineered variants. However, increasing evidence regarding the role of additional FGFs in the regulation of metabolic homeostasis and recent developments regarding novel, engineered FGF variants have revitalized the research interest into the therapeutic potential of certain additional FGFs (e.g. FGF1 and FGF15/FGF19). This review presents a brief overview of the FGF family, describing the mode of action of the different FGFs subgroups, and focuses on FGF1 and FGF15/FGF19, which appear to also represent promising new targets for the treatment of obesity and type 2 diabetes. |
---|---|
AbstractList | The fibroblast growth factor (FGF) family consists of 22 evolutionarily and structurally related proteins (FGF1 to FGF23; with FGF15 being the rodent ortholog of human FGF19). Based on their mechanism of action, FGFs can be categorized into intracrine, autocrine/paracrine and endocrine subgroups. Both autocrine/paracrine and endocrine FGFs are secreted from their cells of origin and exert their effects on target cells by binding to and activating specific single-pass transmembrane tyrosine kinase receptors (FGFRs). Moreover, FGF binding to FGFRs requires specific cofactors, namely heparin/heparan sulfate proteoglycans or Klothos for autocrine/paracrine and endocrine FGF signaling, respectively. FGFs are vital for embryonic development and mediate a broad spectrum of biological functions, ranging from cellular excitability to angiogenesis and tissue regeneration. Over the past decade certain FGFs (e.g. FGF1, FGF10, FGF15/FGF19 and FGF21) have been further recognized as regulators of energy homeostasis, metabolism and adipogenesis, constituting novel therapeutic targets for obesity and obesity-related cardiometabolic disease. Until recently, translational research has been mainly focused on FGF21, due to the pleiotropic, beneficial metabolic actions and the relatively benign safety profile of its engineered variants. However, increasing evidence regarding the role of additional FGFs in the regulation of metabolic homeostasis and recent developments regarding novel, engineered FGF variants have revitalized the research interest into the therapeutic potential of certain additional FGFs (e.g. FGF1 and FGF15/FGF19). This review presents a brief overview of the FGF family, describing the mode of action of the different FGFs subgroups, and focuses on FGF1 and FGF15/FGF19, which appear to also represent promising new targets for the treatment of obesity and type 2 diabetes. |
Author | Gharanei, Seley Weickert, Martin O Kyrou, Ioannis Randeva, Harpal S Tan, Bee K |
Author_xml | – sequence: 1 givenname: Ioannis surname: Kyrou fullname: Kyrou, Ioannis organization: Centre of Applied Biological and Exercise Sciences (ABES), Faculty of Health and Life Sciences, Coventry University, Coventry, UK – sequence: 2 givenname: Martin O surname: Weickert fullname: Weickert, Martin O organization: Centre of Applied Biological and Exercise Sciences (ABES), Faculty of Health and Life Sciences, Coventry University, Coventry, UK – sequence: 3 givenname: Seley surname: Gharanei fullname: Gharanei, Seley organization: Warwick Medical School, University of Warwick, Coventry, UK – sequence: 4 givenname: Harpal S surname: Randeva fullname: Randeva, Harpal S organization: Centre of Applied Biological and Exercise Sciences (ABES), Faculty of Health and Life Sciences, Coventry University, Coventry, UK – sequence: 5 givenname: Bee K surname: Tan fullname: Tan, Bee K email: b.k.tan@warwick.ac.uk organization: Birmingham Heartlands Hospital, Heart of England NHS Foundation NHS Trust, Birmingham, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27412358$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tKAzEYRoMoWquvUPIApuaeiTspVoWC4GVdksyfmYFOpiSR4tsrVVcf5ywOfJfoNE0JEFowuuTCCH37RoVlhFljlkwvKVdCE3qCZqzhhjAt5Dm64EYyLlQzQ6_rwefJ71ypuMvTofY4ulCnXO5wggMeUhm6vpabI1WXO6jlx-LaAx5dch2MkCqeIm4H56FCuUJn0e0KXP_tHH2sH95XT2Tz8vi8ut-QIBirxDGrqNYA2mrlfIw2Mh6kaKOXUUYfITQ8aMFdAG9bFqyx0sjQqgCqoZzP0eK3u__0I7TbfR5Gl7-2_-f4Nx7kUOI |
CitedBy_id | crossref_primary_10_1016_j_clinbiochem_2018_09_003 crossref_primary_10_1186_s12916_017_0797_5 crossref_primary_10_1007_s11695_020_04807_7 crossref_primary_10_1172_JCI164185 crossref_primary_10_3389_fnins_2020_00219 crossref_primary_10_1111_dom_14716 crossref_primary_10_1080_10408363_2020_1864278 crossref_primary_10_1515_mr_2022_0019 crossref_primary_10_1038_s41387_018_0020_6 crossref_primary_10_3390_nu16121938 crossref_primary_10_1016_j_biomaterials_2021_120943 crossref_primary_10_1038_s41419_021_03478_1 crossref_primary_10_3390_ijms22105400 crossref_primary_10_3390_ijms19113597 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.23736/S0391-1977.16.02536-0 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 1827-1634 |
ExternalDocumentID | 27412358 |
Genre | Journal Article Review |
GroupedDBID | CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-c311t-a195066ee6965abff9f12c43dfb4f4fbfec82c632aceb9d1c979474cd5ce58022 |
IngestDate | Tue Jul 04 17:46:40 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c311t-a195066ee6965abff9f12c43dfb4f4fbfec82c632aceb9d1c979474cd5ce58022 |
PMID | 27412358 |
ParticipantIDs | pubmed_primary_27412358 |
PublicationCentury | 2000 |
PublicationDate | 2017-09-01 |
PublicationDateYYYYMMDD | 2017-09-01 |
PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Italy |
PublicationPlace_xml | – name: Italy |
PublicationTitle | Minerva endocrinologica |
PublicationTitleAlternate | Minerva Endocrinol |
PublicationYear | 2017 |
Score | 2.219995 |
SecondaryResourceType | review_article |
Snippet | The fibroblast growth factor (FGF) family consists of 22 evolutionarily and structurally related proteins (FGF1 to FGF23; with FGF15 being the rodent ortholog... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 248 |
SubjectTerms | Animals Diabetes Mellitus - drug therapy Diabetes Mellitus, Type 2 - drug therapy Fibroblast Growth Factors - drug effects Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Obesity - drug therapy |
Title | Fibroblast growth factors: new insights, new targets in the management of diabetes |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27412358 |
Volume | 42 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUWeuFSgVqg5UM-9AZecOI4SW8VAq0qLa34ENyQ7djQwyYrCEjwC_qzO-PE2WgFonCJElvJZj0vL2-cmTEh35I8M0q5GOu2ZkwIVTBteM5kqqMU9rgRmI08Ppajc_HzMrkcDP72opbuaz00T8_mlbzHqtAGdsUs2TdYtrsoNMA-2Be2YGHY_peNj8DXrTTo33rnGtzp-iYsn4N-PuhljDRH59vbCo-buO-7ENw46WJfUDOGadi-Xh1jbuCD2rFlUQG_lC1VdjT9eFvde5qpcO2jTp9f2D_9bKAafu9XF-mDJaJL66MITm34ruw_NZWFffBidqRup1impD8nAe-5EHQFr5SGR7MoZSD1RJ9oRdQDVNxnzabY5jybR3Hq15s5xSr2jINSHXI5BJEWS7bfPwEGdTrxNsZiPJj8-3rvXJXt0LVAFtIMmfL497hJKPd3sffsPWAl6fa8Oa_Eq5OzZfKxdSvojwYjK2Rgy0_kZIYP2uCDtvj4TgENNKBj1x-12IBWCtigM2zQytGAjc_k_Ojw7GDE2jU0mIk5r5nCZX6ltFbmMlHaudzxyIi4cFo44bSzJouMjCNlrM4LbnIg6FSYIjE2wTTsVbJYVqVdJxTGRabKwt8FF1vtc5VpjtXxoszg9KH8QtaaIbiaNoVSrsLgfH2xZ4MszfCzST44eDLtFsi8Wm97G_wDBW9Sng |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fibroblast+growth+factors%3A+new+insights%2C+new+targets+in+the+management+of+diabetes&rft.jtitle=Minerva+endocrinologica&rft.au=Kyrou%2C+Ioannis&rft.au=Weickert%2C+Martin+O&rft.au=Gharanei%2C+Seley&rft.au=Randeva%2C+Harpal+S&rft.date=2017-09-01&rft.eissn=1827-1634&rft.volume=42&rft.issue=3&rft.spage=248&rft_id=info:doi/10.23736%2FS0391-1977.16.02536-0&rft_id=info%3Apmid%2F27412358&rft_id=info%3Apmid%2F27412358&rft.externalDocID=27412358 |